Literature DB >> 6726293

Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside.

J Frick, P S Ritch, R M Hansen, T Anderson.   

Abstract

Conventional therapy for leukemic meningitis includes cranial irradiation and intrathecal chemotherapy administered by repeated lumbar punctures or direct intraventricular instillation via an Ommaya reservoir. Several clinical reports have indicated that high doses of cytosine arabinoside (ara-C) are effective in the treatment of acute leukemia refractory to standard induction therapy. Pharmacokinetic studies have demonstrated that high doses of ara-C given intravenously obtain sustained therapeutic drug concentrations in the cerebrospinal fluid, suggesting that this approach may be useful in the treatment of systemic disease associated with meningeal involvement. Five consecutive patients with overt meningeal leukemia were treated using only systemic chemotherapy containing high-dose ara-C. In all patients there was prompt resolution of neurologic symptoms and signs accompanied by cytologic clearing of leukemic cells from the cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6726293     DOI: 10.1200/JCO.1984.2.5.365

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

Review 1.  Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Authors:  Stacey L Berg; Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

2.  Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; June Takeda; Kazunari Aoki; Tadakazu Kondo; Satoshi Takahashi; Yasushi Onishi; Yukiyasu Ozawa; Nobuyuki Aotsuka; Yasuji Kouzai; Hirohisa Nakamae; Shuichi Ota; Chiaki Nakaseko; Hiroki Yamaguchi; Koji Kato; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.

Authors:  Y Arai; T Kondo; A Shigematsu; J Tanaka; S Takahashi; T Kobayashi; N Uchida; Y Onishi; J Ishikawa; H Kanamori; M Sawa; A Yokota; Y Kouzai; M Takanashi; T Ichinohe; Y Atsuta; S Mizuta
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

Review 4.  Pharmacologic strategies for the treatment of meningeal malignancy.

Authors:  S M Blaney; D G Poplack
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

Review 6.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

7.  Constitutive integrin activation on tumor cells contributes to progression of leptomeningeal metastases.

Authors:  Dieta Brandsma; Laurien Ulfman; Jaap C Reijneveld; Madelon Bracke; Martin J B Taphoorn; Jaap Jan Zwaginga; Martijn F B Gebbink; Hetty de Boer; Leo Koenderman; Emile E Voest
Journal:  Neuro Oncol       Date:  2006-03-13       Impact factor: 12.300

8.  Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.

Authors:  L M DeAngelis; W Kreis; K Chan; E Dantis; S Akerman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  High-dose cytarabine (HD araC) in the treatment of leukemias: a review.

Authors:  Nicholas D Reese; Gary J Schiller
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

10.  Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.

Authors:  J C Scott-Moncrieff; T C Chan; M L Samuels; J R Cook; G L Coppoc; D B DeNicola; R C Richardson
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.